Clinical Trials Logo

Clinical Trial Summary

The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.


Clinical Trial Description

Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03316261
Study type Observational
Source Helmholtz Zentrum München
Contact Anette-Gabriele Ziegler
Phone 0800-000 0018
Email contact@gppad.org
Status Recruiting
Phase
Start date October 19, 2017
Completion date August 2024